Kiniksa Pharmaceuticals International, plc KNSA Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's investment proceeds?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported investment proceeds of $145.66M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's investment proceeds changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's investment proceeds increased by 230.8% year-over-year, from $44.03M to $145.66M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's investment proceeds?
- Over 4 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's investment proceeds has grown at a -10.2% compound annual growth rate (CAGR), from $306.3M to $199.49M.
- What does investment proceeds mean?
- Cash received from sales, maturities, and redemptions of investment securities across all categories.